Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Product

Lumasiran

Aliases
ALN-GO1, OXLUMO
Name
OXLUMO
INN Name
lumasiran
FDA Approved
Yes

7 clinical trials

1 organization

12 indications

1 document

Indication
Primary Hyperoxaluria
Indication
Primary Hyperoxaluria Type 1
Indication
Recurrent Calcium Oxalate Kidney Stone Disease
Indication
Hyperoxaluria
Indication
Hemodialysis
Indication
Chronic Kidney Disease Requiring Chronic Dialysis
Indication
Cardiovascular Disease
Indication
Cardiovascular Risk Factor
Indication
Primary hyperoxaluria type 1 (PH1)
Indication
RNAi Therapeutics
Indication
small interfering RNA
Indication
Angiotensinogen
Clinical trial
Expanded Access Protocol to Provide Lumasiran to Patients With Primary Hyperoxaluria Type 1
Status:
Clinical trial
ILLUMINATE-A: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study With an Extended Dosing Period to Evaluate the Efficacy and Safety of Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1
Status: Completed, Estimated PCD: 2019-11-05
Clinical trial
ILLUMINATE-B: An Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1
Status: Active (not recruiting), Estimated PCD: 2020-06-29
Clinical trial
ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 (PH1)
Status: Active (not recruiting), Estimated PCD: 2021-05-18
Clinical trial
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Lumasiran in Patients With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate Levels
Status: Terminated, Estimated PCD: 2023-01-18
Clinical trial
Lumasiran in Hyperoxalaemic Patients on Haemodialysis
Status: Not yet recruiting, Estimated PCD: 2024-11-30
Clinical trial
A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Administration of ALN-GO1 in Patients With Primary Hyperoxaluria Type 1
Status: Completed, Estimated PCD: 2023-02-07
Document
DailyMed Label: OXLUMO
Organization
Alnylam Pharmaceuticals, Inc.